Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.
暂无分享,去创建一个
P. Armand | D. Fisher | R. Soiffer | Jennifer R. Brown | Yi-Bin Chen | A. El-Jawahri | T. Spitzer | S. McAfee | J. Abramson | E. Hochberg | Shuli Li | C. Cutler | J. Antin | V. Ho | J. Barnes | E. Jacobsen | Candice Del Rio | J. Driscoll | R. Takvorian | S. Mcafee
[1] P. Armand. Immune checkpoint blockade in hematologic malignancies. , 2015, Blood.
[2] V. Bachanova,et al. Role of allogeneic stem cell transplantation in mantle cell lymphoma , 2015, European journal of haematology.
[3] J. Vose,et al. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[4] Marcela V Maus,et al. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. , 2014, Blood.
[5] N. Schmitz,et al. The Role of Allogeneic Stem Cell Transplantation in Hodgkin’s Lymphoma , 2014, Current Treatment Options in Oncology.
[6] A. Salar,et al. Impact of prior rituximab on outcomes of autologous stem‐cell transplantation in patients with relapsed or refractory aggressive B‐cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study , 2014, British journal of haematology.
[7] R. Bouabdallah,et al. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC , 2014, Annals of Hematology.
[8] S. Papageorgiou,et al. The role of allogeneic haematopoietic progenitor cell transplantation in patients with diffuse large B-cell non-Hodgkin lymphomas (DLBCL) , 2013, Bone Marrow Transplantation.
[9] M. Beksac,et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. , 2013, Blood.
[10] A. LaCasce,et al. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era , 2013, British journal of haematology.
[11] R. Bouabdallah,et al. Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin’s lymphoma , 2013, Bone Marrow Transplantation.
[12] J. Vose,et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? , 2012, Blood.
[13] E. Kimby,et al. Nordic MCL2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem‐cell support: still very long survival but late relapses do occur , 2012, British journal of haematology.
[14] J. Delabie,et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] G. Sauvageau,et al. Tandem autologous-allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[16] R. Tsang,et al. Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors , 2012, Leukemia & lymphoma.
[17] M. Pfreundschuh,et al. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[18] N. Geller,et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. , 2011, The Lancet. Oncology.
[19] H. Goldschmidt,et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] J. Wingard,et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. , 2011, Blood.
[21] R. Champlin,et al. Stem-cell transplantation in T-cell non-Hodgkin's lymphomas. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] N. Schmitz,et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] A. LaCasce,et al. Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vinc , 2010, Leukemia & lymphoma.
[24] J. S. San Miguel,et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. , 2008, Blood.
[25] J. Vose,et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[26] J. Bourhis,et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. , 2006, Blood.
[27] E. Shpall,et al. Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients: a feasibility study , 2005, Bone Marrow Transplantation.
[28] A. Romanelli,et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] A. Hagenbeek,et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] A. Hagenbeek,et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.